share_log

Takeda Pharmaceutical | 6-K: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA

SEC announcement ·  Nov 13, 2023 06:05
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more